spacer
home > pmps > winter 2018 > schott’s iqtm platform
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

SCHOTT’S iQTM Platform

More than 600 production lines in 13 countries worldwide produce more than 10 billion syringes, vials, ampoules, cartridges, and special articles of tubing glass or polymer. SCHOTT has more than 130 years of outstanding materials and technology expertise.

iQ™: The Global RTU Standard

Ready-to-use (RTU) filling concepts enable pharma manufacturers to fill syringes, vials, or cartridges in a flexible manner. However, currently available solutions from packaging suppliers require drug manufacturers to fit the filling machines to the specific tub format. This means that the machine needs to be optimised each time to fit the individual products. It also means doing the same work multiple times. With its new iQ platform, SCHOTT addresses this particular issue by standardising ready-to-use syringes, vials, and cartridges within a single tub format to run on the same filling line. By standardising this part of the process, less changing of machine parts is necessary when switching from one container to another as vials, syringes, and cartridges all come in the same tub. Consequently, pharma manufacturers can fill various drug/container configurations on the same filling line with only very short changeover times in between. The development of iQ is based on the proven nest-and-tub format of RTU syringes, which has been used by the pharma industry to fill syringes for decades. Thus, the concept boosts the advantages of RTU filling concepts.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
SCHOTT Pharmaceutical Systems is one of the world’s leading suppliers of parenteral packaging for the pharmaceutical industry
spacer
SCHOTT Pharmaceutical Systems
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement